Novel inhibitor of osteoclast differentiation through regulating MAPKs and Akt signaling pathways

Soluble secreted member of the tumor necrosis factor receptor superfamily, inhibiting osteoclastogenesis by interrupting the signaling between stromal cells and osteoclastic progenitor cells, leading to excess accumulation of bone and cartilage

Novel Inhibitor of Migration and Invasion of Osteosarcoma Cells Mediated by p53, Regulating EMT-Related Genes

Novel Inhibitor of Migration and Invasion of Osteosarcoma Cells Mediated by p53, Regulating EMT-Related Genes

Novel AMPK activator, inhibiting mTOR signaling and autophagy stimulation, activating mutations in RAS or BRAF

Novel potent inhibitor of the natural function of FDX1, promoting a unique form of copper-dependent cell death

Natural inhibitor of the Na+/K+-ATPase sodium-potassium ion pump

High affinity and human/rat species-selective histamine H3 receptor antagonist

Ovalbumin fragment peptide as a class I (Kb)-restricted peptide epitope, triggering T cell activation in immunology studies

Ovalbumin fragment peptide for study class II MHC-peptide binding and T-cell activation, binding to I-A(d) MHC class II protein, encompassing an allergenic and antigenic epitope of the ovalbumin protein

Narural broad anticancer agent, upregulating hsa-miR-155, suppressing the BCR-ABL fusion gene and dysregulating the PI3K/AKT/mTOR pathway

First-in-class small molecule potentiator of cancer virotherapy, significantly enhancing virus replication-associated luciferase expression specifically in the tumor

Novel anthelmintic agent, immobilising whipworm and reducing the ability of embryonated T. muris eggs to establish infection in the mouse host in vivo

Novel anthelmintic agent

Brain penetrant, selective and high affinity OX1R antagonist

Novel selective Ligand for the Orexin 2 Receptor (OX2R)

Potent inhibitor of PANC-1 cell migration and MYPT1 phosphorylation

Novel dual inhibitor of the p53 interaction with MDM2 and MDMX

PPARalpha/gamma agonist

Novel potent inhibitor of GVIA iPLA2 with little or no inhibition against GIVA cPLA2 (XI(50) = 0.0073 and >0.91, respectively)

Novel inhibitor of the bromodomain and extra terminal domain (BET) bromodomain family member BRD4(1)

Dual dopamine D2 and muscarinic M1 receptor ligand with putative antipsychotic and pro-cognitive potential